Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes

Arthritis and Rheumatology

Volumn 66, Issue 3, 2014, Pages 560-568

  Toyoda, Yuko ^a   Tabata, Sho ^a   Kishi, Jun ^a   Kuramoto, Takuya ^a   Mitsuhashi, Atsushi ^a   Saijo, Atsuro ^a   Kawano, Hiroshi ^a   Goto, Hisatsugu ^a   Aono, Yoshinori ^a   Hanibuchi, Masaki ^a   Horikawa, Hideaki ^a   Nakajima, Toshihiro ^b   Furukawa, Tatsuhiko ^c   Sone, Saburo ^a   Akiyama, Shin Ichi ^d   Nishioka, Yasuhiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PROTEIN; SMALL INTERFERING RNA; THYMIDINE PHOSPHORYLASE; TUMOR NECROSIS FACTOR ALPHA; TYMP PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; UPREGULATION;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CHEMOKINE CXCL10; CYTOKINES; HUMANS; INTERFERON-GAMMA; SYNOVIAL MEMBRANE; THYMIDINE PHOSPHORYLASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896289470     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38263     Document Type: Article

References (39)

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res 2008;59: 762-84
2. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993;32:333-8
3. Akiyama S, Furukawa T, Sumizawa T, Takebayashi Y, Nakajima Y, Shimaoka S, et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci 2004;95: 851-7
4. Matsushita S, Nitanda T, Furukawa T, Sumizawa T, Tani A, Nishimoto K, et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res 1999;59:1911-6
5. Takao S, Akiyama S, Nakajo A, Yoh H, Kitazono M, Natsugoe S, et al. Suppression of metastasis by thymidine phosphorylase inhibitor. Cancer Res 2000;60:5345-8
6. Nakajima Y, Gotanda T, Uchimiya H, Furukawa T, Haraguchi M, Ikeda R, et al. Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose. Cancer Res 2004;64:1794-801
7. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 2009;29:903-53
8. Waguri Y, Otsuka T, Sugimura I, Matsui N, Asai K, Moriyama A, et al. Gliostatin/platelet-derived endothelial cell growth factor as a clinical marker of rheumatoid arthritis and its regulation in fibroblast-like synoviocytes. Br J Rheumatol 1997;36:315-21
9. Takeuchi M, Otsuka T, Matsui N, Asai K, Hirano T, Moriyama A, et al. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 1994;37:662-72
10. Ikuta K, Waguri-Nagaya Y, Kikuchi K, Yamagami T, Nozaki M, Aoyama M, et al. The Sp1 transcription factor is essential for the expression of gliostatin/thymidine phosphorylase in rheumatoid fibroblast-like synoviocytes. Arthritis Res Ther 2012;14:R87
11. Canete JD, Matrinez SE, Farres J, Sanmarti R, Blay M, Gomez A, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000;59:263-8
12. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-83
13. Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y, et al. A novel mechanism for the regulation of IFNγ inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 2003;5:R74-81
14. Laragione T, Brenner M, Sherry B, Gulko PS. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum 2011;63:3274-83
15. Lee EY, Seo M, Juhnn YS, Kim JY, Hong YJ, Lee YJ, et al. Potential role and mechanism of IFN-γ inducible protein-10 on receptor activator of nuclear factor κB ligand (RANKL) expression in rheumatoid arthritis. Arthritis Res Ther 2011;13:R104
16. Goto M, Sasano M, Yamanaka H, Miyasaka N, Kamatani N, Inoue K, et al. Spontaneous production of an interleukin 1-like factor by cloned rheumatoid synovial cells in long-term culture. J Clin Invest 1987;80:786-96
17. Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K, et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 1995;38: 485-91
18. Kyhse-Andersen J. Electroblotting of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J Biochem Biophys Methods 1984;10:203-9
19. Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 1996;32A: 1227-32
20. Kwak HB, Ha H, Kim HN, Lee JH, Kim HS, Lee S, et al. Reciprocal cross-talk between RANKL and interferon- γ-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 2008;58:1332-42
21. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka- Benke A, Gal A, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:202-13
22. Manicourt DH, Poilvache P, van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000;43:281-8
23. Partsch G, Wagner E, Leeb BF, Broll H, Dunky A, Smolen JS. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998;57:691-3
24. Tabata S, Ikeda R, Yamamoto M, Furukawa T, Kuramoto T, Takeda Y, et al. Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells. Oncol Rep 2012;28:895-902
25. Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, Sugita Y, et al. Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol 2012;41:170-9
26. Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu T, et al. CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol 2010;37:257-64
27. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, et al. A phase II, randomized, double-blind, placebocontrolled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:1730-9
28. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
29. Ueno A, Yamamura M, Iwahashi M, Okamoto A, Aita T, Ogawa N, et al. The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis. Rheumatol Int 2005;25:361-7
30. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009;1173:310-7
31. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor α and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998;77:2246-51
32. Zhang R, Sun P, Jiang Y, Chen Z, Huang C, Zhang X, et al. Genome-wide haplotype association analysis and gene prioritization identify CCL3 as a risk locus for rheumatoid arthritis. Int J Immunogenet 2010;37:273-8
33. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A 2006;103:3298-303
34. Cho CS, Cho ML, Min SY, Kim WU, Min DJ, Lee SS, et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol 2000;164:5055-61
35. Hermann LM, Pinkerton M, Jennings K, Yang L, Grom A, Sowders D, et al. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol 2005;115:93-101
36. Murata M, Yudo K, Nakamura H, Chiba J, Okamoto K, Suematsu N, et al. Hypoxia upregulates the expression of angiopoietin-like-4 in human articular chondrocytes: role of angiopoietin-like-4 in the expression of matrix metalloproteinases and cartilage degradation. J Orthop Res 2009;27:50-7
37. Kusabe T, Waguri-Nagaya Y, Tanikawa T, Aoyama M, Fukuoka M, Kobayashi M, et al. The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes. Rheumatol Int 2005;25:625-30
38. Yamagami T, Waguri-Nagaya Y, Ikuta K, Aoyama M, Asai K, Otsuka T. FK506 inhibition of gliostatin/thymidine phosphorylase production induced by tumor necrosis factor-α in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 2011;31:903-9
39. Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000;60: 6298-302.